UPDATE: Morgan Stanley Reiterates on Allscripts Healthcare Solutions as Momentum will Continue in 2014

In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Allscripts Healthcare Solutions MDRX, and raised the price target from $20.00 to $21.00. In the report, Morgan Stanley noted, “Allscripts is a diversified HCIT vendor for hospitals, physician practices, and other healthcare providers. New leadership has solidified the existing customer base with increased product quality, investment in R&D, and product roadmap. Leadership position in growing area of Population Health through strategic acquisition of dbMotion. Replacement of EHR systems ahead of Meaningful Use Stage 2 provides an opportunity from both legacy MDRX and implementation of dbMotion. Compelling valuation – trades at a steep discount to HCIT peers.” Allscripts Healthcare Solutions closed on Thursday at $17.22.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsMorgan StanleyRicky R. Goldwasser
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!